Cagri-Sema Blend 10mg
CagriSema — Amylin + GLP-1 Stack Showing 25% Weight Loss
The CagriSema combination of Cagrilintide (amylin) + Semaglutide (GLP-1) demonstrated ~25% body weight reduction in Phase 2 trials — potentially superior to Semaglutide alone. This pre-blended stack replicates the combination being studied in Phase 3.
CagriSema — Amylin + GLP-1 Stack Showing 25% Weight Loss
Cagrilintide adds amylin receptor (CALCR/RAMP) satiety signaling to Semaglutide's GLP-1 receptor pathway, producing additive weight loss in Phase 2 trials. Now in Phase 3 as CagriSema, this is the most clinically advanced amylin-GLP-1 combination.
As one of the most studied compounds in the bundles & stacks research space, CagriSema has attracted sustained scientific interest across CagriSema combination research, Amylin+GLP-1 mechanism studies, Advanced obesity research. Peer-reviewed evidence indicates that ~25% weight loss in Phase 2 CagriSema trials, which has positioned CagriSema as a reference standard for researchers exploring cagrisema combination research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
CagriSema Documented Benefits: 3 Documented Mechanisms
Phase 2 Validated
~25% weight loss in Phase 2 trials — potentially superior to Semaglutide monotherapy.
Dual Amylin + GLP-1 Mechanism
CALCR/RAMP amylin receptor + GLP-1R dual activation for additive appetite suppression.
Phase 3 Pipeline
Replicates the Phase 3 CagriSema combination being studied by Novo Nordisk.
How CagriSema Works: Molecular Mechanism & Pathway
Semaglutide GLP-1R agonism for appetite/insulin + Cagrilintide CALCR/RAMP amylin receptor activation for satiety amplification via complementary pathways.
The 3 primary research pathways identified for CagriSema — Phase 2 Validated, Dual Amylin + GLP-1 Mechanism, Phase 3 Pipeline — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that now in Phase 3 — most advanced amylin+GLP-1 combination, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, CagriSema's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
CagriSema is routinely studied alongside Semaglutide and Cagrilintide in bundles & stacks-focused compound panels. Researchers investigating cagrisema combination research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that additive weight loss vs. Semaglutide alone has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All CagriSema research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- ~25% weight loss in Phase 2 CagriSema trials
- Now in Phase 3 — most advanced amylin+GLP-1 combination
- Additive weight loss vs. Semaglutide alone
Ideal For
- CagriSema combination research
- Amylin+GLP-1 mechanism studies
- Advanced obesity research
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on CagriSema. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
~25% weight loss in Phase 2 CagriSema trials
Now in Phase 3 — most advanced amylin+GLP-1 combination
Additive weight loss vs. Semaglutide alone
Third-Party Verified Every Batch
Each vial of CagriSema is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
